Gut Microbiota-Derived Short-Chain Fatty Acids in Inflammatory Bowel Disease: Mechanistic Insights into Gut Inflammation, Barrier Function, and Therapeutic Potential
International Journal of Molecular Sciences · 22.01.2026 · 27 (2) · 1095
DOI: 10.3390/ijms27021095 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.01.2026. Verfasst von Roberta Ottria und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi di Milano, 20157 Milan, Italy. Hauptthemen laut MEDLINE: Fatty Acids, Volatile, Inflammatory Bowel Diseases, Gastrointestinal Microbiome. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This review delves into the complex relationship between short-chain fatty acids (SCFAs) produced by the gut microbiota and inflammatory bowel disease (IBD). IBD, which includes Crohn’s disease and ulcerative colitis, is a group of chronic gastrointestinal disorders with an increasing global incidence. Despite extensive research, the exact etiopathogenesis remains elusive, although a complex interplay involving genetic predisposition, environmental influences, and abnormal immune responses against commensal gut microbes is widely recognized. SCFAs, primarily acetate and butyrate, emerge as key microbial metabolites derived from the fermentation of dietary fiber. They exert profound effects on gut homeostasis, notably with butyrate serving as an essential energy source for colonocytes, strengthening epithelial integrity, actively modulating local and systemic immune functions, suppressing the expression of pro-inflammatory cytokines, and enhancing mucosal defense mechanisms. However, clinical trials exploring SCFA administration have frequently yielded variable and inconsistent results due to differences in study design and patient characteristics. This review thoroughly analyzes the diverse roles of SCFAs in the large intestine, focusing on the intestinal barrier, immune modulation, and microbiota. It critically examines the therapeutic potential of SCFAs, including acetate and propionate, in addition to the well-known butyrate, in IBD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi di Milano, 20157 Milan, Italy.
ORCID-Profile: Roberta Ottria, Susan Mirmajidi, Pierangela Ciuffreda
Zitieren
APA
Ottria, R., Mirmajidi, S., & Ciuffreda, P. (2026). Gut Microbiota-Derived Short-Chain Fatty Acids in Inflammatory Bowel Disease: Mechanistic Insights into Gut Inflammation, Barrier Function, and Therapeutic Potential. International Journal of Molecular Sciences, 27(2), 1095. https://doi.org/10.3390/ijms27021095
Vancouver
Ottria R, Mirmajidi S, Ciuffreda P. Gut Microbiota-Derived Short-Chain Fatty Acids in Inflammatory Bowel Disease: Mechanistic Insights into Gut Inflammation, Barrier Function, and Therapeutic Potential. International Journal of Molecular Sciences. 2026;27(2):1095. doi:10.3390/ijms27021095
BibTeX
@article{Ottria2026,
author = {Ottria, Roberta and Mirmajidi, Susan and Ciuffreda, Pierangela},
title = {Gut Microbiota-Derived Short-Chain Fatty Acids in Inflammatory Bowel Disease: Mechanistic Insights into Gut Inflammation, Barrier Function, and Therapeutic Potential},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {2},
pages = {1095},
doi = {10.3390/ijms27021095}
}
EUVIMED